EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+13.49%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.37B
AUM Growth
+$1.37B
(+14%)
Cap. Flow
+$26.3M
Cap. Flow
% of AUM
1.92%
Top 10 Holdings %
Top 10 Hldgs %
57.21%
Holding
359
New
25
Increased
122
Reduced
183
Closed
27
Top Buys
| 1 |
Microsoft
MSFT
|
$22.3M |
| 2 |
Pinduoduo
PDD
|
$13.5M |
| 3 |
NIO
NIO
|
$13.1M |
| 4 |
Marvell Technology
MRVL
|
$11.4M |
| 5 |
TSMC
TSM
|
$10.4M |
Top Sells
| 1 |
Qualcomm
QCOM
|
$24.2M |
| 2 |
Legend Biotech
LEGN
|
$19.1M |
| 3 |
Trip.com Group
TCOM
|
$15.6M |
| 4 |
Zai Lab
ZLAB
|
$7.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
$3.55M |
Sector Composition
| 1 | Consumer Discretionary | 36.1% |
| 2 | Technology | 29.22% |
| 3 | Communication Services | 14% |
| 4 | Healthcare | 8.72% |
| 5 | Real Estate | 4.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Travere Therapeutics
TVTX
$1.75B
| $417K | 0.03% |
18,532
+1,781
| +11% | +$40.1K |
|
152
BioMarin Pharmaceuticals
BMRN
$11.3B
| $415K | 0.03% |
4,268
+137
| +3% | +$13.3K |
|
153
Relay Therapeutics
RLAY
$709M
| $415K | 0.03% |
25,192
+512
| +2% | +$8.43K |
|
|
BPMC
154
DELISTED
Blueprint Medicines
BPMC
| $414K | 0.03% |
9,195
+267
| +3% | +$12K |
|
155
TG Therapeutics
TGTX
$5.03B
| $413K | 0.03% |
27,428
-11,965
| -30% | -$180K |
|
156
PACCAR
PCAR
$50.5B
| $412K | 0.03% |
5,627
-364
| -6% | -$26.7K |
|
157
Novavax
NVAX
$1.2B
| $410K | 0.03% |
59,231
+33,630
| +131% | +$233K |
|
158
Alkermes
ALKS
$4.95B
| $409K | 0.03% |
14,513
-2,603
| -15% | -$73.4K |
|
159
Apellis Pharmaceuticals
APLS
$3.51B
| $409K | 0.03% |
6,207
-2,397
| -28% | -$158K |
|
160
Danaher
DHR
$143B
| $409K | 0.03% |
1,830
-49
| -3% | -$11K |
|
161
Neurocrine Biosciences
NBIX
$13.5B
| $408K | 0.03% |
4,031
+425
| +12% | +$43K |
|
162
Ionis Pharmaceuticals
IONS
$9.64B
| $406K | 0.03% |
11,372
+100
| +0.9% | +$3.57K |
|
163
CRISPR Therapeutics
CRSP
$4.82B
| $404K | 0.03% |
8,936
+308
| +4% | +$13.9K |
|
164
Revolution Medicines
RVMD
$7.43B
| $403K | 0.03% |
18,603
+6,162
| +50% | +$133K |
|
165
Intellia Therapeutics
NTLA
$1.26B
| $402K | 0.03% |
10,782
-321
| -3% | -$12K |
|
166
Ultragenyx Pharmaceutical
RARE
$3.04B
| $400K | 0.03% |
9,964
-434
| -4% | -$17.4K |
|
167
Xcel Energy
XEL
$42.8B
| $399K | 0.03% |
5,917
-364
| -6% | -$24.5K |
|
168
Vir Biotechnology
VIR
$765M
| $397K | 0.03% |
17,081
+903
| +6% | +$21K |
|
169
Natera
NTRA
$23B
| $396K | 0.03% |
7,135
-3,948
| -36% | -$219K |
|
|
SAGE
170
DELISTED
Sage Therapeutics
SAGE
| $395K | 0.03% |
9,412
+824
| +10% | +$34.6K |
|
171
Ross Stores
ROST
$49.3B
| $394K | 0.03% |
3,709
-260
| -7% | -$27.6K |
|
172
Old Dominion Freight Line
ODFL
$31.1B
| $392K | 0.03% |
2,298
-166
| -7% | -$28.3K |
|
|
KRTX
173
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $392K | 0.03% |
2,157
+14
| +0.7% | +$2.54K |
|
174
Prothena Corp
PRTA
$452M
| $390K | 0.03% |
8,049
+806
| +11% | +$39.1K |
|
175
BioCryst Pharmaceuticals
BCRX
$1.74B
| $389K | 0.03% |
46,585
+6,330
| +16% | +$52.9K |
|